Chapter 2 74 Table S3. Patient characteristics and treatment outcomes for training and validation set. Training cohort Validation cohort n=43 n=77 Sex P=0.13 Male, no.(%) 18 (42%) 44 (57%) Female, no.(%) 25 (58%) 33 (43%) Age (years), mean (s.d.) P=0.21 64 (8) 62 (9) Smoking (never/ex/current) P=0.84 3/35/5 8/58/11 Pack years, median (IQR) P=0.62 30 (21) 28 (28) PS, no.(%) P=0.53 0 12 (28%) 24 (31%) 1 22 (51%) 43 (56%) ≥2 9 (21%) 10 (13%) Pathology, no.(%) P=0.90 Adeno 26 (60%) 50 (65%) Squamous 9 (21%) 12 (16%) LCNEC, NSCLC-type 1 (2%) 2 (2%) NSCLC, NOS 7 (16%) 13 (17%) Mutations, no. (%) P=0.18 KRAS positive 22 (51%) 29 (38%) PD-L1 TPS, no. (%) Negative <1% P=0.17 22 (51%) 50 (65%) Positive ≥1% 21 (49%) 27 (35%) Negative <50% P=0.39 36 (84%) 69 (90%) Positive ≥50% 7 (16%) 8 (10%) Brain metastases, no. (%) P=1.00 7 (16%) 14 (18%) Treatment, no. (%) P=0.11 Nivolumab 30 (70%) 64 (83%) Pembrolizumab 13 (30%) 13 (17%) Line of treatment, no (%) P=0.19 1 0 (0%) 1 (1%) 2 35 (81%) 52 (68%) >2 8 (19%) 24 (31%) Best Overall Response P=0.47 CR/PR 12 (28%) 12 (16%) SD (PFS ≥6 months) 2 (5%) 11 (14%) SD (PFS <6 months) 2 (5%) 4 (5%) PD 27 (63%) 50 (65%)
RkJQdWJsaXNoZXIy MTk4NDMw